Cargando…
Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions
Cardiomyopathies may be hereditary and associated with a familial predilection. Morbidity and mortality can be caused by heart failure, sudden death, or arrhythmias. Sometimes these events are the first manifestations of cardiovascular disease. Hypertrophic cardiomyopathy and arrhythmogenic cardiomy...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380898/ https://www.ncbi.nlm.nih.gov/pubmed/37510821 http://dx.doi.org/10.3390/jcm12144706 |
_version_ | 1785080309020098560 |
---|---|
author | Couto, José F. Martins, Elisabete |
author_facet | Couto, José F. Martins, Elisabete |
author_sort | Couto, José F. |
collection | PubMed |
description | Cardiomyopathies may be hereditary and associated with a familial predilection. Morbidity and mortality can be caused by heart failure, sudden death, or arrhythmias. Sometimes these events are the first manifestations of cardiovascular disease. Hypertrophic cardiomyopathy and arrhythmogenic cardiomyopathy are perhaps most thoroughly studied in that context. Dilated cardiomyopathy, although most frequently of secondary etiology, has a significant familial cluster. Noncompaction of the left ventricle can sometimes be seen in healthy individuals and, in other instances, is associated with severe LV dysfunction. Genetic testing is of utmost importance, since it might allow for the identification of individuals carrying mutations predisposing them to these diseases. In addition, certain variants may benefit from tailored therapeutic regimens, and thus searching for a causal mutation can impact clinical practice and is recommended for all patients with HCM or ACM. Patients with DCM and positive family history should be included as well. Regular follow-ups are advised, even in those with negative phenotypes, because these disorders are often age dependent. During pregnancy and in the case of athletes, special consideration should be made as well. We intend to summarize the most current evidence regarding their management. |
format | Online Article Text |
id | pubmed-10380898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103808982023-07-29 Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions Couto, José F. Martins, Elisabete J Clin Med Review Cardiomyopathies may be hereditary and associated with a familial predilection. Morbidity and mortality can be caused by heart failure, sudden death, or arrhythmias. Sometimes these events are the first manifestations of cardiovascular disease. Hypertrophic cardiomyopathy and arrhythmogenic cardiomyopathy are perhaps most thoroughly studied in that context. Dilated cardiomyopathy, although most frequently of secondary etiology, has a significant familial cluster. Noncompaction of the left ventricle can sometimes be seen in healthy individuals and, in other instances, is associated with severe LV dysfunction. Genetic testing is of utmost importance, since it might allow for the identification of individuals carrying mutations predisposing them to these diseases. In addition, certain variants may benefit from tailored therapeutic regimens, and thus searching for a causal mutation can impact clinical practice and is recommended for all patients with HCM or ACM. Patients with DCM and positive family history should be included as well. Regular follow-ups are advised, even in those with negative phenotypes, because these disorders are often age dependent. During pregnancy and in the case of athletes, special consideration should be made as well. We intend to summarize the most current evidence regarding their management. MDPI 2023-07-15 /pmc/articles/PMC10380898/ /pubmed/37510821 http://dx.doi.org/10.3390/jcm12144706 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Couto, José F. Martins, Elisabete Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions |
title | Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions |
title_full | Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions |
title_fullStr | Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions |
title_full_unstemmed | Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions |
title_short | Recommendations for the Management of Cardiomyopathy Mutation Carriers: Evidence, Doubts, and Intentions |
title_sort | recommendations for the management of cardiomyopathy mutation carriers: evidence, doubts, and intentions |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380898/ https://www.ncbi.nlm.nih.gov/pubmed/37510821 http://dx.doi.org/10.3390/jcm12144706 |
work_keys_str_mv | AT coutojosef recommendationsforthemanagementofcardiomyopathymutationcarriersevidencedoubtsandintentions AT martinselisabete recommendationsforthemanagementofcardiomyopathymutationcarriersevidencedoubtsandintentions |